Vertex files for expanded use of Kalydeco; BMS pulls lots of injectable Coumadin;

@FiercePharma: Top-read FP news yesterday: Sex, bribes and videotape: Clandestine video of GSK exec adds to China scandal. Report | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: ICYMI: FDA approves Ranbaxy's generic Diovan at Indian drugmaker's Ohm plant in New Jersey. Story | Follow @EricPFierce

@CarlyHFierce: Prevnar use in seniors is cost-effective now, CDC says. But will it last? FierceVaccines story | Follow @CarlyHFierce

> Vertex Pharmaceuticals ($VRTX) asked the FDA to expand use of its cystic fibrosis drug Kalydeco, to patients with a common mutation related to the disease. Release

> Bristol-Myers Squibb ($BMY) recalled 6 lots of injectable Coumadin after finding particulate matter in a small number of unreleased samples. Report

> Federal prosecutors urged a New York judge not to dismiss False Claims Act complaints against Novartis in a case involving alleged kickbacks to pharmacies. Report (reg. req.)

> Pfizer ($PFE) persuaded a Pennsylvania federal judge to exclude an expert witness in litigation over its antidepressant Zoloft and its potential inks to birth defects. Report

> Médecins Sans Frontiéres won approval from South African officials to import a cheap generic version of the anti-tuberculosis drug linezolid to allow it to treat more patients. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Neuro-stimulator startup electroCore secures Series A expansion to $50M. Article | Follow @FierceMedDev

@StacyALawrence: Study: One-third of knee replacements are inappropriate. More | Follow @StacyALawrence

@VarunSaxena2: ICYMI yesterday: Stryker to buy Small Bone Innovations for up to $375M. Story | Follow @VarunSaxena2

@MichaelGFierce: Nanoparticles designed to prevent cancer, aid bones. More | Follow @MichaelGFierce

@EmilyWFierce: GPS tracking devices used to prevent injuries in U.S. Men's National Soccer Team players. Bloomberg story | Follow @EmilyWFierce

> Report: $2.3B in digital health venture financing in the first half. Item

> FDA clears 3D virtual reality device for surgical procedures. News

> In obesity device race, ReShape lines up with FDA. More

Biotech News

@FierceBiotech: 's gaze puts the brakes on 's plans for major M&A. ICYMI yesterday | Follow @FierceBiotech

@JohnCFierce: Biotech IPO scorecard: Hits, runs and errors mount in 9th inning frenzy (it's getting crazy out there). Report | Follow @JohnCFierce

@DamianFierce: A truly disruptive, outcomes-driven look at biotech's new nonsense. Xconomy piece | Follow @DamianFierce

@EmilyMFierce: ICYMI: Experimental heart disease vaccine lowers plaque in mice arteries. FierceBiotech Research article | Follow @EmilyMFierce

> Agenus spikes on positive data for its brain cancer vaccine. Story

> Sanofi bumps stake in Regeneron to 22.5%. Item

> Paratek absorbs the troubled Transcept in a reverse merger. Article

> Angling for early OK, Amgen wins 'breakthrough' title for leukemia drug. News

> Bluebird bio snares gene-editing tech in $156M buyout deal. Report

Biotech Research News

> New antibiotic may combat drug-resistant tuberculosis. Story

> Enzyme inhibitor could curb post-stroke injury. More

> Alzheimer's compound targets abnormal blood clots in brain. Story

> Experimental heart disease vaccine lowers arterial plaque in mice. Article

> Pfizer to partner with South African university on preclinical research. Item

Pharma Manufacturing News

> Teva growth hormone for children recalled after oil leaks into product. News

> Manufacturing questions lead to another CRL for Allergan migraine drug. Report

> Janssen will stop making antibiotic Levaquin. Item

> India's IPA hires consulting firm to help it overcome bad publicity. News

> Cipla buys capacity in Yemen with deal to control company there. Article

> FDA OKs Ranbaxy New Jersey plant to make generic Diovan. Story

And Finally... Stress is literally a killer in China, where about 600,000 people--including those in their twenties--die each year from working too hard. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.